Theriva Biologics (NYSEAMERICAN:TOVX) Posts Earnings Results, Misses Expectations By $0.56 EPS

Theriva Biologics (NYSEAMERICAN:TOVX) posted its quarterly earnings data on Tuesday. The company reported ($6.81) EPS for the quarter, missing analysts’ consensus estimates of ($6.25) by ($0.56), Zacks reports.

Theriva Biologics Price Performance

TOVX stock traded down $0.02 during mid-day trading on Wednesday, reaching $1.41. The company had a trading volume of 161,549 shares, compared to its average volume of 1,006,108. The firm has a market capitalization of $3.20 million, a P/E ratio of -0.04 and a beta of 1.34. Theriva Biologics has a fifty-two week low of $1.24 and a fifty-two week high of $17.11.

Wall Street Analysts Forecast Growth

Separately, Maxim Group dropped their price target on Theriva Biologics from $25.00 to $6.00 and set a “buy” rating for the company in a research report on Wednesday.

Theriva Biologics Company Profile

Theriva Biologics, Inc, a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States. The company’s lead product candidate is VCN-01, a clinical stage oncolytic human adenovirus that is in a Phase 2 clinical study for the treatment of pancreatic cancer; a Phase 1 clinical study for the treatment of retinalblastoma; a Phase 1 clinical study for the treatment of head and neck squamous cell carcinoma; and a Phase 1 clinical study for the treatment of solid tumors.